Combination Therapy to Treat Hepatitis B Virus
First Claim
1. A method for the treatment of hepatitis B virus in a human comprising administering in combination or alternation a synergistically effective amount of β
- -2 hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (β
-FTC) or a pharmaceutically acceptable salt, ester, or prodrug thereof with an effective amount of a second anti-hepatitis B agent selected from the group consisting of famciclovir and Bis-POM-PMEA.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
-
Citations
8 Claims
-
1. A method for the treatment of hepatitis B virus in a human comprising administering in combination or alternation a synergistically effective amount of β
- -2 hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (β
-FTC) or a pharmaceutically acceptable salt, ester, or prodrug thereof with an effective amount of a second anti-hepatitis B agent selected from the group consisting of famciclovir and Bis-POM-PMEA. - View Dependent Claims (2, 3, 4)
- -2 hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (β
-
5. A pharmaceutical composition for the treatment of hepatitis B virus in a human comprising an effective amount of β
- -2-hydroxymethyl-5 -(5-fluorocytosin-1-yl)-1,3 oxathiolane (β
-FTC) or a pharmaceutically acceptable salt, ester, or prodrug thereof in a synergistic combination with an effective amount of a second anti-hepatitis B agent selected from the group consisting of famciclovir and Bis-POM-PMEA. - View Dependent Claims (6, 7, 8)
- -2-hydroxymethyl-5 -(5-fluorocytosin-1-yl)-1,3 oxathiolane (β
Specification